10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q1 2017

Filing Information

Form Type	10-Q
Accession Number	`0001532176-17-000017`
Period End Date	20170331
Filing Date	20170504
Fiscal Year	2017
Fiscal Period	Q1
XBRL Instance	regn-20170331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 48 Cash Flow Statement 56

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$811.77M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$604.21M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$495.31M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$503.48M	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.34B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.34B	USD	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$92.99M	USD	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$214.27M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$195.49M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$175.26M	USD	Point-in-time
Inventories	`InventoryNet`	$399.36M	USD	Point-in-time
Inventories	`InventoryNet`	$466.58M	USD	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$130.53M	USD	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$146.06M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.67B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.18B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$967.70M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$864.26M	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.08B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.28B	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$825.30M	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$866.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$20.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$37.09M	USD	Point-in-time
Total assets	`Assets`	$7.82B	USD	Point-in-time
Total assets	`Assets`	$6.97B	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.06B	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$879.10M	USD	Point-in-time
Capital and facility lease obligations, current	`Capitalandfacilityleaseobligationscurrent`	$129.56M	USD	Point-in-time
Capital and facility lease obligations, current	`Capitalandfacilityleaseobligationscurrent`	$7.20M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$115.27M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$112.16M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$126.26M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$116.40M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.18M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$876.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.24B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.31B	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$520.19M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$503.47M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$316.23M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$327.30M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$351.57M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$700.41M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$106.25M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$100.39M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.95B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.52B	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.03B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.19B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.00B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.75B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.88M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-12.84M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.45B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.87B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$6.97B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$7.82B	USD	Point-in-time

Income Statement 48 line items

Line Item	Tag	Value	Unit	Period
Net product sales	`SalesRevenueGoodsNet`	$784.18M	USD	1 Quarter
Net product sales	`SalesRevenueGoodsNet`	$858.25M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$219.69M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$210.37M	USD	1 Quarter
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$193.94M	USD	1 Quarter
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$179.59M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$17.38M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$56.44M	USD	1 Quarter
Total revenues	`Revenues`	$1.32B	USD	1 Quarter
Total revenues	`Revenues`	$1.20B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$507.44M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$470.11M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$296.85M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$289.68M	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$78.94M	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$61.25M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$22.91M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$32.81M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$888.45M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$871.54M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$430.54M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$329.31M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$9.25M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$3.48M	USD	1 Quarter
Interest expense	`InterestIncomeExpenseNonoperatingNet`	$-2.64M	USD	1 Quarter
Interest expense	`InterestIncomeExpenseNonoperatingNet`	$-7.50M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$1.75M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$843.00K	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$432.29M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$330.15M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$183.36M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$148.77M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$2.36	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$1.74	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$1.59	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$2.16	USD	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	104.29M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	105.57M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.11M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.23M	shares	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Unrealized gain (loss) on marketable securities, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-4.21M	USD	1 Quarter
Unrealized gain (loss) on marketable securities, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$6.96M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$177.18M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$255.89M	USD	1 Quarter

Cash Flow Statement 56 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income	`NetIncomeLoss`	$181.38M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$38.12M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$22.98M	USD	1 Quarter
Non-cash compensation expense	`ShareBasedCompensation`	$142.25M	USD	1 Quarter
Non-cash compensation expense	`ShareBasedCompensation`	$133.79M	USD	1 Quarter
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-3.96M	USD	1 Quarter
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-3.96M	USD	1 Quarter
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$40.99M	USD	1 Quarter
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$79.78M	USD	1 Quarter
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$137.93M	USD	1 Quarter
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$397.43M	USD	1 Quarter
Increase in Inventories	`IncreaseDecreaseInInventories`	$69.74M	USD	1 Quarter
Increase in Inventories	`IncreaseDecreaseInInventories`	$62.26M	USD	1 Quarter
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$20.32M	USD	1 Quarter
(Increase) decrease in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-39.26M	USD	1 Quarter
Increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$12.40M	USD	1 Quarter
Increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$91.20M	USD	1 Quarter
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$187.69M	USD	1 Quarter
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$103.43M	USD	1 Quarter
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-136.40M	USD	1 Quarter
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$106.97M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$355.90M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$44.99M	USD	1 Quarter
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	-	USD	1 Quarter
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$208.69M	USD	1 Quarter
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$60.41M	USD	1 Quarter
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$119.01M	USD	1 Quarter
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$50.46M	USD	1 Quarter
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$104.09M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-140.14M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-43.69M	USD	1 Quarter
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$57.00M	USD	1 Quarter
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	1 Quarter
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebt`	$598.00K	USD	1 Quarter
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebt`	$12.86M	USD	1 Quarter
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	-	USD	1 Quarter
Repayments of convertible senior notes	`RepaymentsOfConvertibleDebt`	$1.74M	USD	1 Quarter
Payments in connection with deduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	-	USD	1 Quarter
Payments in connection with deduction of outstanding warrants	`PaymentsForRepurchaseOfWarrants`	$242.12M	USD	1 Quarter
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$16.67M	USD	1 Quarter
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$39.30M	USD	1 Quarter
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	-	USD	1 Quarter
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$1.04M	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$60.81M	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-206.19M	USD	1 Quarter
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$276.57M	USD	1 Quarter
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-204.89M	USD	1 Quarter
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$811.77M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$604.21M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$811.77M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$535.20M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$604.21M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$809.10M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.